Interventional device developer Boston Scientific of Natick, MA, said that it has enrolled its 400th patient in its global Taxus Liberté registry.
The firm plans to enroll more than 30,000 patients at more than 600 centers in the U.S., Europe, and other international locations. The registry is designed to collect and analyze clinical outcomes data for the Taxus Liberté paclitaxel-eluting stent system in the treatment of patients with coronary artery disease, according to the company.
By AuntMinnie.com staff writers
May 26, 2005
Related Reading
Boston Scientific posts strong Q1, April 20, 2005
Boston Scientific purchases CryoVascular Systems, April 19, 2005
Boston Scientific buys TriVascular, April 18, 2005
Boston Scientific acts to acquire Rubicon, April 15, 2005
Boston Scientific gets FDA approval for Liberté stent, April 14, 2005
Copyright © 2005 AuntMinnie.com
